MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
The Consumer Technology Association (CTA) has announced a new Health AI standard, CTA2135: Performance Verification and Validation for Predictive Health AI Solutions. This standard is designed to ensure predictive AI tools in healthcare are accurate, reliable, and ready for deployment. The announcement was made at the CTA’s Health AI+ event at Hopkins Bloomberg Center.
CTA President Kinsey Fabrizio emphasized how the new standard is aimed at helping developers to fulfill AI’s promise of solving significant challenges that address patient and provider needs.
Also released was a CTA research report titled "AI’s Impact and Opportunity Among Healthcare Practitioners," which finds that although AI adoption in healthcare is still nascent, many clinicians are optimistic about what the tools could do, especially for reducing administrative burden, improving documentation, and freeing up time for patient care. The new CTA-2135 release is another of CTA’s extensive portfolio of health-focused AI standards and research.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Olympus has launched the VISERAS OTV-S500, its newest imaging platform, designed for ear, nose, and throat (ENT) and urological procedures. The system is designed for both office and outpatient settings, offering flexible and rigid endoscope compatibility, along with a built-in lighting system that supports switching between white light, stroboscopy mode, and Narrow Band Imaging (NBI).
A key feature of the VISERA S system is its tight integration with Olympus’s content management tools, including the nCare medical recorder and VaultStream system, enabling clinicians to capture procedural recordings and share data across sites within a facility. Olympus also emphasized that NBI technology has been shown to reduce recurrence in non-muscle invasive bladder cancer (NMIBC) by about 37% over a follow-up period of 1,235 months compared with white light cystoscopy alone. The VISERA S Video is not suitable for cardiac applications, but its main features include improved color, depth, and resolution for a clear view of vascular structures.
Olympus Corporation is a global medical technology company committed to providing minimally invasive treatments to improve patient outcomes with elevated standards of care.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Eleos Health has launched Groups, a feature in its documentation platform aimed at simplifying individual speaker notes from group substance use disorder (SUD) therapy sessions. The new tool automatically produces individual speaker summaries from group sessions, whether in-person or via telehealth, while ensuring privacy standards are met to help organizations maintain compliance and reduce administrative overhead.
The Groups capability works with any EHR system and integrates with Eleos’s existing documentation tools. Audio is processed in real time in a HIPAA-compliant environment; Eleos does not save raw session audio, protecting patient privacy. According to Eleos, the solution helps clinicians generate more than 80% of progress note content, with over 90% of notes submitted within 24 hours, and reduces documentation time by over 70%.
Eleos serves more than 200 organizations and more than 35,000 providers. CEO Alon Joffe said the tool supports scaling group therapy sustainably and improving revenue consistency for SUD treatment entities. The key benefits of Groups will help SUD organizations with a reduction in admin, streamlined documentation and provides support to clinical teams by freeing up time. Eleos will demonstrate the new feature at its Summer Launch Event on September 17.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Intrinsic Therapeutics, a medical technology company, has successfully implanted its Barricaid Annular Closure Device in several patients while they remained awake, marking the first time this procedure has been done without general anesthesia. Dr. Ernest E. Braxton Jr., a neurosurgeon specializing in awake and minimally invasive spine surgery, performed the operations in Vail, Colorado.
The new approach uses local and regional anesthesia, enabling patients to provide real-time feedback during the procedure to confirm that nerve pressure has been relieved. Dr. Braxton has been performing awake surgery for more than a decade. Some benefits include a faster recovery period, reduced pain, and fewer risks commonly associated with general anesthesia, such as nausea or postoperative confusion.
Barricaid is a device designed to reduce reherniation and reoperation rates in patients with significant annular defects following lumbar discectomy surgery. It has been implanted in more than 12,000 patients, with clinical studies, including randomized controlled trials and six single-arm studies.
Posted by MedCloudInsider Editors on 09/21/20250 comments
Lightbeam Health Solutions said on Tuesday it has received Microsoft’s AI Cloud Partner Program Healthcare AI Certified software designation for its population health management platform.
The Dallas-based company, which provides AI-enabled tools and services for care coordination, is one of 10 organizations worldwide to receive the designation. Microsoft’s certification verifies that software meets standards for security, interoperability and performance, and is designed to give healthcare providers confidence in adopting cloud-based AI systems.
Lightbeam said the recognition reinforces its collaboration with Microsoft and supports its strategy of using artificial intelligence to help hospitals, health systems and insurers improve quality of care while lowering costs. The company has offered AI-driven healthcare technologies since 2009 and provides services for accountable care organizations, Medicare Advantage, Medicaid and commercial populations.
Chief Technology Officer Michael Hoxter said the certification demonstrates Lightbeam’s focus on delivering secure, validated technology for value-based care. Microsoft’s worldwide healthcare and life sciences lead, Elena Bonfiglioli, said the designation highlights Lightbeam’s early adoption of AI and ability to deliver results in a tight labor market.
The company recently reported that Saint Peter’s University Hospital used its AI platform to cut emergency department visits by 7%.
Posted by MedCloudInsider Editors on 09/17/20250 comments
U.S. health technology company Tellihealth said on Tuesday it has added new features to its Evelyn platform, which combines remote patient monitoring (RPM) with chronic care management (CCM).
The updates include a dashboard that gives call agents and nurses real-time patient information, templates to guide remote patient assessments, a mobile app for patients to track readings and receive reminders, and a game-based feature to encourage daily participation.
Tellihealth said the enhancements are designed to improve clinical workflows, increase patient engagement, and support integration with electronic health record (EHR) systems.
The company, created through the merger of Accuhealth and Signallamp Health, positions Evelyn as a scalable platform for hospitals, health systems, and clinics. It plans deeper interoperability across care settings to generate more data-driven insights for clinicians and patients.
Chief Technology Officer John Kalivas, who joined in April, is leading development of the next-generation system. Chief Executive Asif Ahmad said the upgrades are aimed at simplifying remote care and improving outcomes through tighter EHR integration.
Posted by MedCloudInsider Editors on 09/17/20250 comments
The U.S. Food and Drug Administration has granted breakthrough device designation to SpinaFX Medical’s Triojection system, a minimally invasive treatment for contained lumbar disc herniations, the Canadian company said on Wednesday.
The image-guided procedure uses a proprietary oxygen-ozone delivery system inserted into the spinal disc to reduce pressure and relieve nerve compression. The treatment can be performed on an outpatient basis in hospitals, ambulatory surgical centers, or clinics with minimal infrastructure, SpinaFX said.
The designation gives developers prioritized access to the FDA for feedback and review, aimed at accelerating regulatory clearance for devices addressing serious conditions.
SpinaFX said Triojection is intended as a targeted alternative to conservative care or invasive surgery, offering potential benefits in safety, recovery time and cost. The company added that international studies support the technology, with further trial results expected.
Posted by MedCloudInsider Editors on 08/20/20250 comments
A new startup, BIOPAC Medical Systems LP, has launched following a licensing agreement between Johns Hopkins Applied Physics Laboratory, Johns Hopkins School of Medicine, and medical device firms to commercialize neural blockade monitoring technology. The device provides real-time, objective evaluation of regional anesthetic effectiveness during surgical procedures.
The technology was invented by former APL engineer Wayne Sternberger and pediatric anesthesiologist Dr. Robert Greenberg to address a critical gap in clinical care. Currently, clinicians lack reliable ways to evaluate nerve block effectiveness, particularly in vulnerable patients like children or those under general anesthesia.
"We're putting medical innovation into practice, transforming a pioneering concept into a potentially life-enhancing tool for clinical care," Sternberger said in a statement. The venture received support from Maryland's innovation initiative and a National Science Foundation grant, positioning it for regulatory approval and commercial deployment.
Posted by MedCloudInsider Editors on 08/20/20250 comments
NeuroOne Medical Technologies received FDA clearance for its OneRF ablation system to treat trigeminal neuralgia, a chronic facial pain condition affecting about 150,000 Americans annually. The minimally invasive device uses radiofrequency energy to create lesions that interrupt pain signals from the trigeminal nerve. The Eden Prairie, Minnesota-based company plans a limited launch in Q4 2024, marking its first expansion into chronic pain treatment beyond neurosurgery applications. CEO Dave Rosa said the company expects to pursue additional pain management opportunities, including lower back pain treatments, leveraging its technology platform.
Posted by MedCloudInsider Editors on 08/20/20250 comments